Alnylam Pharmaceuticals Grants Special \$18 Million Performance-Based Equity Award to CEO Dr. Yvonne Greenstreet
Key Points
- Special Equity Award Granted: Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) has granted a special performance-based equity award to its CEO, Dr. Yvonne Greenstreet, effective March 2, 2026.
- Potential Value of \$18 Million: The award is tied to aggressive stock price appreciation targets and could be worth up to \$36 million if the maximum thresholds are met.
- Performance-Based Vesting: Vesting is entirely dependent on Alnylam’s stock price performance over the next several years, with a minimum threshold set well above the current all-time high.
- Strong Track Record: Dr. Greenstreet’s leadership has resulted in nearly 100% shareholder returns, the successful launch of key drugs, and achieving profitability in 2025.
- Strategic Retention and Incentive: The award is designed to retain and incentivize Dr. Greenstreet as Alnylam embarks on its next five-year growth phase, dubbed “Alnylam 2030.”
- No Emerging Growth Company Status: Alnylam is not classified as an emerging growth company, indicating it is a mature, established business.
Details of the Special Equity Award
On March 2, 2026, Alnylam’s Board of Directors, acting on the recommendation of the People, Culture, and Compensation Committee and with the support of an independent compensation consultant, granted Dr. Yvonne Greenstreet a special, fully performance-based equity award under the company’s Second Amended and Restated 2018 Stock Incentive Plan.
The award consists of 55,373 performance share units (“Target Shares”), which, at the closing price of \$325.07 per share, represents a face value of approximately \$18 million. Depending on the company’s future stock performance, Dr. Greenstreet could ultimately vest between 50% and 200% of the Target Shares, or up to 110,746 shares (worth about \$36 million at the grant-date price).
Vesting Criteria and Potential Shareholder Impact
- Vesting Period: The award will vest based on the highest average closing price of Alnylam’s common stock over a 30-consecutive-trading-day period in the six months immediately prior to December 31, 2029 (“Vesting Date”), unless a change in control occurs earlier.
- Stock Price Thresholds:
- \$500/share: 27,687 shares (50% of Target Shares) vest
- \$600/share: 55,373 shares (100% of Target Shares) vest
- \$700/share: 83,060 shares (150% of Target Shares) vest
- \$800/share: 110,746 shares (200% of Target Shares) vest
- All-or-Nothing Baseline: If the stock does not reach at least \$500 during the measurement period, the entire award is forfeited.
- Stock Price Increase Required: These thresholds represent increases of approximately 54%, 85%, 115%, and 146% over the grant-date price, setting an ambitious bar for value realization.
- Linear Interpolation: Vesting scales linearly between the defined thresholds.
Strategic Rationale and Importance to Shareholders
This special award underscores the Board’s confidence in Dr. Greenstreet’s leadership and the importance of her retention as Alnylam pursues its next phase of growth. Under her stewardship, Alnylam has:
- Delivered nearly 100% shareholder return during her tenure as CEO.
- Launched AMVUTTRA in multiple indications, including a landmark approval for TTR cardiomyopathy in 2025.
- Built a robust clinical pipeline with over 25 active programs, including three new Phase 3 trials.
- Achieved or exceeded all announced “Alnylam P5x25″ goals, including reaching profitability in 2025.
The Board sees the Special Award as a prudent tool to both incentivize and ensure stable leadership as the company aims for its new “Alnylam 2030” aspirations.
Other Notable Information
- Governance: The award is subject to Alnylam’s policy for the recovery of erroneously awarded incentive-based compensation (clawback policy).
- Regulatory Filings: The form of the award agreement will be filed with the SEC as an exhibit to the company’s Q1 2026 10-Q report.
- No Change to Annual Grants: This special award is in addition to, and concurrent with, annual executive equity awards.
Potential Share Price Impact
This announcement is potentially highly price sensitive for several reasons:
- Signals Ambitious Share Price Targets: The award structure makes clear management’s and the Board’s belief in Alnylam’s ability to substantially increase shareholder value over the next four years.
- Retention of Key Executive: The retention of Dr. Greenstreet, whose leadership has driven significant value creation, is intended to provide stability and continuity as the company pursues its long-term goals.
- Direct Alignment with Shareholder Interests: Since the award only pays out if the share price rises significantly, Dr. Greenstreet’s incentives are tightly aligned with those of shareholders.
- Possible Market Perception: Investors may interpret the aggressive targets as an indicator of confidence in the company’s future or as a challenge to achieve such growth, potentially increasing volatility in share price as the market digests the news.
Conclusion
Alnylam’s special, performance-based equity grant to CEO Dr. Yvonne Greenstreet is a bold move designed to secure leadership, drive ambitious growth, and closely align executive compensation with shareholder returns. The award’s value, and the high bar for vesting, make this a potentially significant development for investors watching the company’s trajectory toward 2030.
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own research and consult with a qualified financial advisor before making investment decisions. The information presented is based on filings and disclosures deemed reliable as of the date of publication, but no warranty is made as to its accuracy or completeness. Alnylam Pharmaceuticals and its officers may be subject to additional risks and uncertainties not fully disclosed in this article.
View ALNYLAM PHARMACEUTICALS, INC. Historical chart here
